Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

1.

Reduced-Intensity Conditioning Hematopoietic Cell Transplantation Is an Effective Treatment for Patients with SLAM-Associated Protein Deficiency/X-linked Lymphoproliferative Disease Type 1.

Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1641-5. doi: 10.1016/j.bbmt.2014.06.003. Epub 2014 Jun 9.

PMID:
24923536
[PubMed - in process]
2.

An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis.

Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, Kumar A, Jodele S, Myers KC, Chandra S, Leemhuis T, Mehta PA, Bleesing JJ, Davies SM, Jordan MB, Filipovich AH.

Biol Blood Marrow Transplant. 2013 Nov;19(11):1625-31. doi: 10.1016/j.bbmt.2013.09.001. Epub 2013 Sep 10.

PMID:
24035782
[PubMed - indexed for MEDLINE]
3.

Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation.

Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH.

Blood. 2010 Dec 23;116(26):5824-31. doi: 10.1182/blood-2010-04-282392. Epub 2010 Sep 20.

PMID:
20855862
[PubMed - indexed for MEDLINE]
Free Article
4.

Lymphoproliferative Disease, X-Linked.

Filipovich A, Johnson J, Zhang K, Marsh R.

In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014.
2004 Feb 27 [updated 2013 Sep 19].

PMID:
20301580
[PubMed]
Books & Documents
5.

Extracorporeal photophoresis: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1.

PMID:
23074497
[PubMed]
Free PMC Article
6.

Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.

Hamidieh AA, Pourpak Z, Hashemi S, Yari K, Fazlollahi MR, Movahedi M, Behfar M, Moin M, Ghavamzadeh A.

Eur J Haematol. 2014 Apr;92(4):331-6. doi: 10.1111/ejh.12244. Epub 2014 Jan 10.

PMID:
24330187
[PubMed - in process]
7.

Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.

Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.

PMID:
23664940
[PubMed - indexed for MEDLINE]
9.

Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.

Cesaro S, Gazzola MV, Marson P, Calore E, Caenazzo L, Destro R, De Silvestro G, Varotto S, Pillon M, Zanesco L, Messina C.

Am J Hematol. 2003 Feb;72(2):143-6.

PMID:
12555220
[PubMed - indexed for MEDLINE]
10.

Low-dose total body irradiation, fludarabine, and antithymocyte globulin conditioning for nonmyeloablative allogeneic transplantation.

Grosskreutz C, Ross V, Scigliano E, Fruchtman S, Isola L.

Biol Blood Marrow Transplant. 2003 Jul;9(7):453-9.

PMID:
12869959
[PubMed - indexed for MEDLINE]
11.

A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.

Kröger N, Schetelig J, Zabelina T, Krüger W, Renges H, Stute N, Schrum J, Kabisch H, Siegert W, Zander AR.

Bone Marrow Transplant. 2001 Oct;28(7):643-7.

PMID:
11704786
[PubMed - indexed for MEDLINE]
Free Article
12.

Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.

Devine SM, Sanborn R, Jessop E, Stock W, Huml M, Peace D, Wickrema A, Yassine M, Amin K, Thomason D, Chen YH, Devine H, Maningo M, van Besien K.

Bone Marrow Transplant. 2001 Sep;28(6):557-62.

PMID:
11607768
[PubMed - indexed for MEDLINE]
Free Article
13.

Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease.

Oshrine BR, Olson TS, Bunin N.

Pediatr Blood Cancer. 2014 Oct;61(10):1852-9. doi: 10.1002/pbc.25113. Epub 2014 Jun 17.

PMID:
24939325
[PubMed - in process]
14.

Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.

Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.

Biol Blood Marrow Transplant. 2013 Jun;19(6):981-7. doi: 10.1016/j.bbmt.2013.03.016. Epub 2013 Apr 2.

PMID:
23562738
[PubMed - indexed for MEDLINE]
15.

Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.

Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9. doi: 10.1016/j.bbmt.2007.12.488.

PMID:
18275894
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes.

Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH.

Blood. 2013 Feb 7;121(6):877-83. doi: 10.1182/blood-2012-06-432500. Epub 2012 Nov 6.

PMID:
23131490
[PubMed - indexed for MEDLINE]
Free Article
17.

Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.

Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG.

Biol Blood Marrow Transplant. 2011 Jul;17(7):1051-7. doi: 10.1016/j.bbmt.2010.11.004. Epub 2010 Nov 10.

PMID:
21073974
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma.

Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S.

Blood. 2004 Dec 15;104(13):3865-71. Epub 2004 Aug 10.

PMID:
15304395
[PubMed - indexed for MEDLINE]
Free Article
19.

Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.

Lush RJ, Haynes AP, Byrne J, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Lui Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.

Cytotherapy. 2001;3(3):203-10.

PMID:
12171727
[PubMed - indexed for MEDLINE]
20.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk